Treatment decision-making in men with localized prostate cancer living in a remote area: A cross-sectional, observational study.


Journal

Canadian Urological Association journal = Journal de l'Association des urologues du Canada
ISSN: 1911-6470
Titre abrégé: Can Urol Assoc J
Pays: Canada
ID NLM: 101312644

Informations de publication

Date de publication:
Mar 2021
Historique:
pubmed: 19 8 2020
medline: 19 8 2020
entrez: 19 8 2020
Statut: ppublish

Résumé

For the management of localized prostate cancer, patient treatment choice is poorly documented among people living in remote areas, where access to certain treatments offered in large centers involves travelling several hundred kilometres. This study aimed to describe and identify the determinants of treatment decision-making in men with localized prostate cancer living in remote areas. In this cross-sectional study, patients with prostate cancer were recruited from Rouyn-Noranda's urology clinic (Quebec, Canada) between 2017 and 2019. A total of 127 men (mean age 68.34±7.23 years) constituted the study sample. Radiotherapy, a treatment not available locally, was chosen most frequently (67.7%), followed by options available locally, such as surgery (22.8%) and active surveillance (9.4%). Most patients preferred to play an active role in this choice (53.5%) and agreed with the statement, "I chose that treatment because it gives the best chance for a cure" (86.6%). Multiple logistic regression analysis revealed that cancer stage (odds ratio [OR] 10.15; 95% confidence interval [CI] 3.18-32.40) was the only factor associated with radiotherapy choice (patients with lower stage cancer were more likely to choose radiotherapy). The socioeconomic status was not associated with treatment choice. While radiotherapy was not available locally, it was the most frequently chosen treatment, even though the available literature suggests that no one treatment option is superior in terms of cancer control. The choice of radiotherapy is not associated with patient income, but rather the cancer stage. This result could be explained by the patients' desire to avoid surgery and its adverse effects.

Identifiants

pubmed: 32807284
pii: cuaj.6521
doi: 10.5489/cuaj.6521
pmc: PMC7943242
doi:

Types de publication

Journal Article

Langues

eng

Pagination

E160-E168

Références

Prostate. 2010 Aug;70(11):1255-64
pubmed: 20658653
Cancer. 2005 Oct 1;104(7):1381-90
pubmed: 16080181
J Racial Ethn Health Disparities. 2016 Mar;3(1):35-45
pubmed: 26896103
Cancer Nurs. 2012 Nov-Dec;35(6):411-8
pubmed: 22067700
Cancer Nurs. 2002 Feb;25(1):42-9
pubmed: 11838719
Am J Mens Health. 2018 Sep;12(5):1635-1647
pubmed: 29877127
Patient Educ Couns. 1990 Feb;15(1):49-64
pubmed: 2290741
Fam Pract. 2017 Feb;34(1):90-97
pubmed: 28034917
Urology. 2009 Sep;74(3):509-15
pubmed: 19589564
Biomed Res Int. 2017;2017:1467056
pubmed: 28785574
Radiother Oncol. 2016 Jan;118(1):85-91
pubmed: 26780999
CA Cancer J Clin. 2017 May 6;67(3):245-253
pubmed: 28222223
BJU Int. 2011 Jun;107(11):1762-8
pubmed: 21083643
Psychooncology. 2018 Jan;27(1):325-332
pubmed: 28612468
Urol Nurs. 2017 Jan-Feb;37(1):15-22
pubmed: 29240360
Can Fam Physician. 2013 Dec;59(12):1269-74
pubmed: 24336537
Patient Educ Couns. 2013 Jan;90(1):61-8
pubmed: 22940374
Bull Cancer. 2013 Mar;100(3):191-9
pubmed: 23500637
Urol Oncol. 2018 Apr;36(4):183-192
pubmed: 29122446
J Clin Epidemiol. 1992 Sep;45(9):941-50
pubmed: 1432023
Urol Oncol. 2016 May;34(5):233.e17-25
pubmed: 26705101
Curr Oncol. 2010 Aug;17(4):85-93
pubmed: 20697520
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
J Cancer Educ. 2016 Jun;31(2):301-7
pubmed: 25893926
World J Urol. 2017 Apr;35(4):595-603
pubmed: 27447989
Curr Opin Urol. 2008 May;18(3):275-8
pubmed: 18382237
Oncol Nurs Forum. 1995 Oct;22(9):1401-8
pubmed: 8539181
J Cancer Educ. 2018 Feb;33(1):180-185
pubmed: 27418065
Future Oncol. 2008 Aug;4(4):561-8
pubmed: 18684066
Can J Urol. 2008 Dec;15(6):4415-20
pubmed: 19046495
Oncol Nurs Forum. 2009 Jan;36(1):89-96
pubmed: 19136342
J Psychosom Res. 2000 Jul;49(1):13-9
pubmed: 11053599
Semin Urol Oncol. 2002 Feb;20(1):55-62
pubmed: 11828358
J Am Board Fam Med. 2012 Nov-Dec;25(6):763-70
pubmed: 23136314
Urology. 1989 May;33(5 Suppl):57-62
pubmed: 2523612
Curr Oncol. 2016 Feb;23(1):56-9
pubmed: 26966405
BMJ Open. 2017 Sep 15;7(9):e015154
pubmed: 28918408
Med Decis Making. 2017 Jan;37(1):56-69
pubmed: 27510740
Can Fam Physician. 2010 Aug;56(8):e308-14
pubmed: 20705870
Curr Oncol. 2015 Dec;22(6):427-9
pubmed: 26715876
CMAJ. 2016 May 17;188(8):E141-E147
pubmed: 26927971
Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1240-50
pubmed: 27257092
Can Oncol Nurs J. 2015 Spring;25(2):157-78
pubmed: 26638285
Cancer. 2006 May 1;106(9):1865-74
pubmed: 16568450
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):313-317
pubmed: 27496390
Arthritis Rheum. 2003 Apr 15;49(2):156-63
pubmed: 12687505
Can Urol Assoc J. 2017 Oct;11(10):298-309
pubmed: 29381452
BMC Urol. 2017 Oct 27;17(1):98
pubmed: 29078772

Auteurs

Abir El-Haouly (A)

Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue (UQAT), Rouyn-Noranda, QC, Canada.

Alice Dragomir (A)

Department of Surgery, Division of Urology, McGill University, Montreal, QC, Canada.
Research Institute, McGill University Health Centre, Montreal, QC, Canada.

Hares El-Rami (H)

Centre hospitalier de Rouyn-Noranda, Centre intégré de santé et de services sociaux (CISSS) de l'Abitibi-Témiscamingue, Rouyn-Noranda, QC, Canada.

Frédéric Liandier (F)

Centre hospitalier de Rouyn-Noranda, Centre intégré de santé et de services sociaux (CISSS) de l'Abitibi-Témiscamingue, Rouyn-Noranda, QC, Canada.

Anaïs Lacasse (A)

Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue (UQAT), Rouyn-Noranda, QC, Canada.

Classifications MeSH